PureTech’s idiopathic pulmonary fibrosis (IPF) candidate, deupirfenidone, is ready to enter a pivotal study after showing improved efficacy compared with standard treatment in a Phase II study.
The product (also known as LYT-100) is a deuterated version of the former Roche blockbuster Esbriet (pirfenidone) and is one...